Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Post by 2skytracker2on May 07, 2012 4:28pm
351 Views
Post# 19881551

Reply from MacMicken !

Reply from MacMicken !

Mr. MacMicken replied to my email on May 3rd. in which I questioned the practicallity of a reverse split of 1 for 10 shares and why the name change?.............Explaination for the name change makes perfect sense to me as the new name is reflective of the Company being based in Columbia "(Santa Maria is the ship Columbus was on when he discovered America)" and the old name is representative of Guatamala...Quetzal is the name of thier national bird...the company no longer holds assets in Guatamala.

To the second ? I asked about the stock split. I was informed that many institutional investors have a mandate in thier charter that will not allow them to purchase shares under
.10,
.50 etc. and that when these investors make a purchase they buy anywhere from $500,000 to $2,000,000 at a time and they dont want to be buying 50,000,000 shares at a time............to make a long story short the board believes that having over 600 million shares outstanding is keeping a lot potential investors away.To this I replied, that I believed 10 for 1 is extreme and gets a NO! vote from me and reminded Mr. MacMicken that only 1 year ago that an analyst had a
.25 one year target on this stock! with 600 million shares OS and said the stock price will rise when results are produced and it really dosn't matter how many shares are outstanding. I dont know if this will do any good but I hope its a resonable representation of the small investor!! 

Bullboard Posts